Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

IISc SraVaani: India's First Open-Source Speech Recognition Model for 65 Languages

IISc's SPIRE Lab, in collaboration with ARTPARK and Google, has released SraVaani – the first multilingual Indian speech recognition model trained on 65 languages and dialects. It extends ASR to 45 underserved regional languages, potentially benefiting 25 crore people. This marks a major step in inclusive AI for India's linguistic diversity.

VP Launches India Valve Registry for Heart Valve Disease Research; TN Reports 2,590 Valve Replacements in 20 Months

The Vice-President launched the India Valve Registry, a first-of-its-kind clinician-led platform to collect real-world data on valvular heart disease and interventions in India. The registry will generate India-specific evidence to improve patient care, while Tamil Nadu's CMCHIS data reveals 2,590 valve replacements in 20 months, highlighting the burden of rheumatic heart disease and the success of state-led healthcare.

Stem Cell Therapy for Autism Restricted to Clinical Trials; Health Ministry Advisory Follows SC Order

The Union Health Ministry has reiterated that stem cell therapy for Autism Spectrum Disorder (ASD) can only be offered as part of approved clinical trials, not as routine or commercial treatment. This follows a landmark Supreme Court judgment in January 2026 that examined the issue. The advisory reinforces existing regulations under the Clinical Establishments Act, 2010, and the National Guidelines for Stem Cell Research, 2017.

ICMR Study: 61% Gram-Negative Infections Carbapenem-Resistant; Mortality 39-51%

A large ICMR study across 20 Indian hospitals (2022-2025) reveals that carbapenem-resistant Gram-negative infections cause significantly higher mortality (39-51% in bloodstream infections) and cost 1.1-2 times more to treat. The study stresses that antimicrobial resistance is a complex interplay of healthcare transmission, antibiotic pressure, and diagnostic gaps, not just antibiotic overuse.

India's AI Pipeline: 43% Women STEM Graduates, Only 10% in Leadership – Need for Inclusive AI

India's AI ambition faces a hidden gender crisis: women drop from 43% of STEM graduates to just 10% of senior AI leadership. This pipeline leakage, driven by social barriers and digital divide, risks automating existing inequalities. For exam aspirants, this article provides critical data on gender disparity in tech and the imperative for inclusive AI development.

RK-251: India's ROS-Activated Smart Cancer Drug Could Transform Chemotherapy

RK-251 is a novel 'smart' cancer drug developed by Indian researchers that activates only inside cancer cells using high reactive oxygen species (ROS) levels, potentially reducing chemotherapy side effects. This marks a significant advancement in targeted cancer therapy and is a key topic for UPSC Science & Technology.

CDSCO Approves Qdenga: India's First Dengue Vaccine to be Distributed by Dr Reddy's from 2027

India’s first approved dengue vaccine Qdenga will enter the private market in 2027 via Dr Reddy’s, after CDSCO approval in July 2026. The vaccine is effective against all four serotypes, requires no pre-vaccination screening, and shows 61.2% efficacy against dengue and 84.1% against hospitalization. This is a landmark step in India's fight against dengue.